AASLD Practice Guideline

You have free access to this content

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases†‡§

  1. Marc G. Ghany1,¶,*,
  2. David R. Nelson2,
  3. Doris B. Strader3,
  4. David L. Thomas4,
  5. Leonard B. Seeff5

Article first published online: 26 SEP 2011

DOI: 10.1002/hep.24641

Issue

Hepatology

Hepatology

Volume 54, Issue 4, pages 1433–1444, October 2011

Additional Information

How to Cite

Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L. and Seeff, L. B. (2011), An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54: 1433–1444. doi: 10.1002/hep.24641

Author Information

  1. 1

    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

  2. 2

    Section of Hepatobiliary Disease, University of Florida, Gainesville, FL

  3. 3

    Gastroenterology and Hepatology Division, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT

  4. 4

    Johns Hopkins Medical Institution, Baltimore, MD

  5. 5

    The Hill Group, Bethesda, MD

  1. fax: 301-402-0491

*Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-16, 10 Center Drive, MSC 1800, Bethesda, MD 20892-1800

  1. †

    Potential conflict of interest: Dr. Nelson receives research support from Vertex, Merck, Phamassett, Genentech/Roche, Gilead, Bristol-Myers Squibb, Tibotec, Bayer/Onyx and serves on advisory boards of Merck, Pharmassett, Genentech/Roche, Gilead, Tibotec, and Bayer/Onyx, and is a consultant for Vertex.Dr. Thomas receives research support from Merck, Gilead and serves on a Merck advisory board.Dr. Ghany, Dr. Seeff, and Dr. Strader have nothing to report.

  2. ‡

    Consultant in Hepatology for the U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20943. The views expressed in the document are those of the authos and not of the Food and Drug Administration.

  3. §

    All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material.

  4. fax: 301-402-0491

Publication History

  1. Issue published online: 27 SEP 2011
  2. Article first published online: 26 SEP 2011
  3. Accepted manuscript online: 2 SEP 2011 09:28AM EST
  4. Manuscript Received: 29 AUG 2011
  5. Manuscript Accepted: 29 AUG 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (270K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    [Draft] Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drug and Biological Products, Biotechnology Law Report, 2013, 32, 1-2, 58

    CrossRef

  2. 2
    Venessa Pattullo, Andres Duarte-Rojo, Wael Soliman, Florencia Vargas-Vorackova, Sanjeev Sockalingam, Ivan G. Fantus, Johane Allard, Jenny Heathcote, A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C, Liver International, 2013, 33, 3
    Direct Link:
  3. 3
    K. Neukam, C. Almeida, A. Caruz, A. Rivero-Juarez, N. I. Rallon, F. A. Di Lello, R. Herrero, A. Camacho, J. M. Benito, J. Macias, A. Rivero, V. Soriano, J. A. Pineda, A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients, Journal of Antimicrobial Chemotherapy, 2013, 68, 4, 915

    CrossRef

  4. 4
    Eric Lawitz, Fred Poordad, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Sara Siggelkow, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Tami Pilot-Matias, Barry Bernstein, A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1, Journal of Hepatology, 2013,

    CrossRef

  5. You have free access to this content5
    A. H. Talal, J. LaFleur, R. Hoop, P. Pandya, P. Martin, I. Jacobson, J. Han, E. J. Korner, Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients, Alimentary Pharmacology & Therapeutics, 2013, 37, 4
    Direct Link:
  6. 6
    Jérôme Dumortier, Olivier Guillaud, Marie-Claude Gagnieu, Bénédicte Janbon, Laurent Juillard, Emmanuel Morelon, Vincent Leroy, Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?, Journal of Clinical Virology, 2013, 56, 2, 146

    CrossRef

  7. 7
    Fabrizio Fabrizi, Vivek Dixit, Piergiorgio Messa, Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: Meta-analysis of clinical studies, Journal of Medical Virology, 2013, 85, 6
    Direct Link:
  8. 8
    Carmen Vinaixa, Victoria Aguilera, Marina Berenguer, Avances en el tratamiento de la hepatitis C, Medicina Clínica, 2013,

    CrossRef

  9. 9
    Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass, Antoine C El Khoury, Fred Poordad, Jean-Pierre Bronowicki, Elamin H Elbasha, Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study, BMC Infectious Diseases, 2013, 13, 1, 190

    CrossRef

  10. 10
    Yoshiyasu Karino, Joji Toyota, Kenji Ikeda, Fumitaka Suzuki, Kazuaki Chayama, Yoshiiku Kawakami, Hiroki Ishikawa, Hideaki Watanabe, Dennis Hernandez, Fei Yu, Fiona McPhee, Hiromitsu Kumada, Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir, Journal of Hepatology, 2013, 58, 4, 646

    CrossRef

  11. 11
    E. Lontok, N. Mani, P. R. Harrington, V. Miller, Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy, Clinical Infectious Diseases, 2013, 56, 10, 1466

    CrossRef

  12. 12
    M. H. Eckman, A. H. Talal, S. C. Gordon, E. Schiff, K. E. Sherman, Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States, Clinical Infectious Diseases, 2013, 56, 10, 1382

    CrossRef

  13. 13
    T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, New England Journal of Medicine, 2013, 368, 20, 1907

    CrossRef

  14. 14
    M. S. Sulkowski, Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection, Journal of Infectious Diseases, 2013, 207, suppl 1, S26

    CrossRef

  15. 15
    Satoru Joshita, Kumiko Shirahata, Yoshikazu Yazaki, Shinji Okaniwa, Yoshiyuki Nakamura, Takefumi Kimura, Sugiko Noami, Reiko Horigome, Hikaru Yagi, Nobuo Ito, Asami Yamazaki, Yuki Akahane, Takeji Umemura, Kaname Yoshizawa, Eiji Tanaka, Masao Ota, Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy, Hepatology Research, 2013, 43, 5
    Direct Link:
  16. 16
    Fernando E. Membreno, Jennifer C. Espinales, Eric J. Lawitz, Cyclophilin Inhibitors for Hepatitis C Therapy, Clinics in Liver Disease, 2013, 17, 1, 129

    CrossRef

  17. 17
    Katja Deterding, Norbert Grüner, Peter Buggisch, Johannes Wiegand, Peter R Galle, Ulrich Spengler, Holger Hinrichsen, Thomas Berg, Andrej Potthoff, Nisar Malek, Anika Großhennig, Armin Koch, Helmut Diepolder, Stefan Lüth, Sandra Feyerabend, Maria Christina Jung, Magdalena Rogalska-Taranta, Verena Schlaphoff, Markus Cornberg, Michael P Manns, Heiner Wedemeyer, Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial, The Lancet Infectious Diseases, 2013,

    CrossRef

  18. 18
    Hee-Young Kim, Xiaolan Li, Christopher T. Jones, Charles M. Rice, Jean-Michel Garcia, Auguste Genovesio, Michael A.E. Hansen, Marc P. Windisch, Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals, Antiviral Research, 2013, 99, 1, 6

    CrossRef

  19. 19
    Jennifer J. Kiser, Charles Flexner, Direct-Acting Antiviral Agents for Hepatitis C Virus Infection, Annual Review of Pharmacology and Toxicology, 2013, 53, 1, 427

    CrossRef

  20. 20
    Alessio Aghemo, Elisabetta Degasperi, Massimo Colombo, Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials, Digestive and Liver Disease, 2013, 45, 1, 1

    CrossRef

  21. 21
    Peter N. Morcos, Rohit Kulkarni, Sally Scoon, Patrick F. Smith, Barbara J. Brennan, Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study, Drug Development Research, 2013, 74, 3
    Direct Link:
  22. 22
    Jacqueline G. O'Leary, Gregory J. McKenna, Göran B. Klintmalm, Gary L. Davis, Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients, Liver Transplantation, 2013, 19, 4
    Direct Link:
  23. 23
    A. Calcagno, L. Boglione, F. G. De Rosa, G. Di Perri, S. Bonora, Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1, Clinical Infectious Diseases, 2013, 56, 11, 1677

    CrossRef

  24. 24
    Akbar Ali, Cihan Aydin, Reinhold Gildemeister, Keith P. Romano, Hong Cao, Ayşegül Özen, Djade Soumana, Alicia Newton, Christos J. Petropoulos, Wei Huang, Celia A. Schiffer, Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance, ACS Chemical Biology, 2013, 130501131703009

    CrossRef

  25. 25
    Joseph Kluck, Rose M. O’Flynn, David E. Kaplan, Kyong-Mi Chang, Evaluation of the Significance of Pretreatment Liver Biopsy and Baseline Mental Health Disorder Diagnosis on Hepatitis C Treatment Completion Rates at a Veterans Affairs Medical Center, Hepatitis Research and Treatment, 2013, 2013, 1

    CrossRef

  26. 26
    Verónica Saludes, Fernando González-Candelas, Ramón Planas, Ricard Solà, Vicente Ausina, Elisa Martró, Evolutionary dynamics of the E1–E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b, Infection, Genetics and Evolution, 2013, 13, 1

    CrossRef

  27. 27
    Nikolaos Papadopoulos, Spilios Manolakopoulos, Melanie Deutsch, Maria Mela, Aggeliki Christidou, Athina Katoglou, Dimitrios Tzourmakliotis, George V. Papatheodoridis, Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece, European Journal of Gastroenterology & Hepatology, 2013, 25, 5, 587

    CrossRef

  28. 28
    Savino Bruno, Alessandra Mangia, Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era, Digestive and Liver Disease, 2013, 45, 5, 356

    CrossRef

  29. 29
    Denis R. St. Laurent, Michael H. Serrano-Wu, Makonen Belema, Min Ding, Hua Fang, Min Gao, Jason T. Goodrich, Rudolph G. Krause, Julie A. Lemm, Mengping Liu, Omar D. Lopez, Van N. Nguyen, Peter T. Nower, Donald R. O’Boyle, Bradley C. Pearce, Jeffrey L. Romine, Lourdes Valera, Jin-Hua Sun, Ying-Kai Wang, Fukang Yang, Xuejie Yang, Nicholas A. Meanwell, Lawrence B. Snyder, HCV NS5A Replication Complex Inhibitors. Part 4.(1) Optimization for Genotype 1a Replicon Inhibitory Activity, Journal of Medicinal Chemistry, 2013, 130410085046001

    CrossRef

  30. 30
    Bryan Cobb, Paul J Pockros, Regis A Vilchez, John M Vierling, HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals, The American Journal of Gastroenterology, 2013, 108, 4, 471

    CrossRef

  31. 31
    Fabrizio Fabrizi, Emmanuelle Plaisier, David Saadoun, Paul Martin, Piergiorgio Messa, Patrice Cacoub, Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease, American Journal of Kidney Diseases, 2013, 61, 4, 623

    CrossRef

  32. 32
    Lisa C. Casey, William M. Lee, Hepatitis C virus therapy update 2013, Current Opinion in Gastroenterology, 2013, 1

    CrossRef

  33. You have free access to this content33
    Salvatore Petta, Antonio Craxì, How to optimize HCV therapy in genotype 1 patients: predictors of response, Liver International, 2013, 33,
    Direct Link:
  34. You have free access to this content34
    Eleonora Grassi, Alessio Aghemo, How to optimize HCV therapy in genotype 2 patients, Liver International, 2013, 33,
    Direct Link:
  35. 35
    A. S. Rangnekar, R. J. Fontana, IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis, Journal of Viral Hepatitis, 2013, 20, 6
    Direct Link:
  36. 36
    Andrew J. Muir, IL28B in the Era of Direct-acting Antivirals for Hepatitis C, Journal of Clinical Gastroenterology, 2013, 47, 3, 222

    CrossRef

  37. 37
    M. Afshar, A.D. Martinez, R.L. Gallo, T.R. Hata, Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: A review and analysis of 36 cases, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 6
    Direct Link:
  38. 38
    Marcus Adrian Cheek, Mariam L. Sharaf, Mikhail I. Dobrikov, Barbara Ramsay Shaw, Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: Exploring a potential strategy for mechanism-based HCV drug design, Antiviral Research, 2013, 98, 2, 144

    CrossRef

  39. 39
    Daryl T.–Y. Lau, Amina Negash, Jie Chen, Nanette Crochet, Mala Sinha, Yuhong Zhang, Jeremie Guedj, Sharon Holder, Takeshi Saito, Stanley M. Lemon, Bruce A. Luxon, Alan S. Perelson, Michael Gale, Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection, Gastroenterology, 2013, 144, 2, 402

    CrossRef

  40. 40
    Markus H. Heim, Innate immunity and HCV, Journal of Hepatology, 2013, 58, 3, 564

    CrossRef

  41. 41
    Stephen A. Harrison, Djamal Abdurakhmanov, Mitchell L. Shiffman, Igor Bakulin, Wlodzimierz Mazur, Maribel Rodriguez-Torres, Giovanni Faria Silva, Hugo Cheinquer, Diethelm Messinger, Edward V. Connell, Michael McKenna, Fernando Tatsch, K. Rajender Reddy, Intensified Peginterferon α-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein, Journal of Clinical Gastroenterology, 2013, 47, 3, 271

    CrossRef

  42. 42
    Ajay Duseja, Interferon-Free Regimens for Chronic Hepatitis C—A Step Forward, Journal of Clinical and Experimental Hepatology, 2013, 3, 1, 76

    CrossRef

  43. 43
    Stéphanie Pascarella, Sophie Clément, Michael T. Dill, Stéphanie Conzelmann, Martin Lagging, Gabriele Missale, Avidan U. Neumann, Jean-Michel Pawlotsky, Stefan Zeuzem, Laura Rubbia-Brandt, Pierre-Yves Bochud, Francesco Negro, Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C, Liver International, 2013, 33, 1
    Direct Link:
  44. 44
    Andrew Aronsohn, Andrew J. Muir, Tracy Swan, Donald Jensen, Is the HCV Pipeline Heading in the Right Direction?, Gastroenterology, 2013, 144, 3, 482

    CrossRef

  45. 45
    Sudhakar K. Venkatesh, Meng Yin, Richard L. Ehman, Magnetic resonance elastography of liver: Technique, analysis, and clinical applications, Journal of Magnetic Resonance Imaging, 2013, 37, 3
    Direct Link:
  46. 46
    James R. Burton, Gregory T. Everson, Management of the Transplant Recipient with Chronic Hepatitis C, Clinics in Liver Disease, 2013, 17, 1, 73

    CrossRef

  47. You have free access to this content47
    M. Romero-Gómez, R. Planas, J. Ampuero, R. Solà, J. García-Samaniego, M. Diago, J. Crespo, J. L. Calleja, J. Turnes, Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 37, 11
    Direct Link:
  48. 48
    Tatsuo Kanda, Shingo Nakamoto, Makoto Arai, Tatsuo Miyamura, Shuang Wu, Keiichi Fujiwara, Osamu Yokosuka, Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient, Clinical Journal of Gastroenterology, 2013, 6, 2, 160

    CrossRef

  49. 49
    Dennis Hernandez, Nannan Zhou, Joseph Ueland, Aaron Monikowski, Fiona McPhee, Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors, Journal of Clinical Virology, 2013, 57, 1, 13

    CrossRef

  50. 50
    S. D. Holmberg, M. Lu, L. B. Rupp, L. E. Lamerato, A. C. Moorman, V. Vijayadeva, J. A. Boscarino, E. M. Henkle, S. C. Gordon, S. D. Holmberg, E. H. Teshale, P. R. Spradling, A. C. Moorman, S. C. Gordon, D. R. Nerenz, M. Lu, L. Lamerato, L. B. Rupp, N. Akkerman, N. J. Oja-Tebbe, C. M. Cogan, D. Larkin, J. A. Boscarino, Z. S. Daar, R. E. Smith, P. J. Curry, B. D. Geise, J. B. Leader, C. C. Nakasato, V. Vijayadeva, K. E. Sylva, J. V. Parker, M. M. Schmidt, E. M. Henkle, T. L. Dodge, E. M. Keast, L. Drew, Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort, Clinical Infectious Diseases, 2013,

    CrossRef

  51. 51
    Urs A. Meyer, Ulrich M. Zanger, Matthias Schwab, Omics and Drug Response, Annual Review of Pharmacology and Toxicology, 2013, 53, 1, 475

    CrossRef

  52. You have free access to this content52
    Benjamin Maasoumy, Michael P. Manns, Optimal treatment with boceprevir for chronic HCV infection, Liver International, 2013, 33,
    Direct Link:
  53. You have free access to this content53
    Mitchell L. Shiffman, Yves Benhamou, Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?, Liver International, 2013, 33,
    Direct Link:
  54. 54
    Karin Neukam, Pablo Barreiro, Antonio Rivero-Juárez, Antonio Caruz, José A. Mira, Angela Camacho, Juan Macías, Antonio Rivero, Vicente Soriano, Juan A. Pineda, Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response, Journal of Infection, 2013,

    CrossRef

  55. 55
    Z. Jin, V. Leveque, H. Ma, K. A. Johnson, K. Klumpp, PNAS Plus: NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase, Proceedings of the National Academy of Sciences, 2013, 110, 5, E348

    CrossRef

  56. 56
    Takeshi Nishimura, Kanji Yamaguchi, Hideki Fujii, Yorihisa Okada, Chihiro Yokomizo, Toshihisa Niimi, Yoshio Sumida, Kohichiroh Yasui, Hironori Mitsuyoshi, Masahito Minami, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh, Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study, Hepatology Research, 2013, 43, 5
    Direct Link:
  57. 57
    Chung-Feng Huang, Ming-Lung Yu, Jia-Horng Kao, Tai-Chung Tseng, Ming-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Suh-Hang Hank Juo, Wan-Long Chuang, Chen-Hua Liu, Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype, Journal of Clinical Virology, 2013, 56, 4, 293

    CrossRef

  58. You have free access to this content58
    Tsunamasa Watanabe, Yasuhito Tanaka, Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy, Hepatology Research, 2013, 43, 2
    Direct Link:
  59. 59
    Jiang Liu, Pravin R. Jadhav, Shashi Amur, Russell Fleischer, Thomas Hammerstrom, Linda Lewis, Lisa Naeger, Jule O'Rear, Michael Pacanowski, Sarah Robertson, Shirley Seo, Greg Soon, Debra Birnkrant, Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects, Hepatology, 2013, 57, 3
    Direct Link:
  60. You have free access to this content60
    J. H. Lewis, J. G. Stine, Review article: prescribing medications in patients with cirrhosis – a practical guide, Alimentary Pharmacology & Therapeutics, 2013, 37, 12
    Direct Link:
  61. You have free access to this content61
    D. Joshi, I. Carey, K. Agarwal, Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients, Alimentary Pharmacology & Therapeutics, 2013, 37, 7
    Direct Link:
  62. 62
    C.-M. Liang, T.-H. Hu, S.-N. Lu, C.-H. Hung, C.-M. Huang, J.-H. Wang, Y.-H. Yen, C.-H. Chen, K.-C. Chang, M.-C. Tsai, Y.-H. Kuo, C.-M. Lee, Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy, Journal of Viral Hepatitis, 2013, 20, 6
    Direct Link:
  63. 63
    Humberto C. Gonzalez, Syed Mohammed Jafri, Stuart C Gordon, Role of Liver Biopsy in the Era of Direct-Acting Antivirals, Current Gastroenterology Reports, 2013, 15, 2

    CrossRef

  64. 64
    Rosângela Teixeira, Yone de Almeida Nascimento, Déborah Crespo, Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions, The Brazilian Journal of Infectious Diseases, 2013, 17, 2, 194

    CrossRef

  65. 65
    Zuzanna Makowska, Tanja Blumer, François H.T. Duong, Nicola La Monica, Ekambar R. Kandimalla, Markus H. Heim, Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist, Journal of Hepatology, 2013, 58, 4, 743

    CrossRef

  66. 66
    Eric Lawitz, Alessandra Mangia, David Wyles, Maribel Rodriguez-Torres, Tarek Hassanein, Stuart C. Gordon, Michael Schultz, Mitchell N. Davis, Zeid Kayali, K. Rajender Reddy, Ira M. Jacobson, Kris V. Kowdley, Lisa Nyberg, G. Mani Subramanian, Robert H. Hyland, Sarah Arterburn, Deyuan Jiang, John McNally, Diana Brainard, William T. Symonds, John G. McHutchison, Aasim M. Sheikh, Zobair Younossi, Edward J. Gane, Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, 2013, 368, 20, 1878

    CrossRef

  67. 67
    Eric Lawitz, Jay P Lalezari, Tarek Hassanein, Kris V Kowdley, Fred F Poordad, Aasim M Sheikh, Nezam H Afdhal, David E Bernstein, Edwin DeJesus, Bradley Freilich, David R Nelson, Douglas T Dieterich, Ira M Jacobson, Donald Jensen, Gary A Abrams, Jama M Darling, Maribel Rodriguez-Torres, K Rajender Reddy, Mark S Sulkowski, Natalie H Bzowej, Robert H Hyland, Hongmei Mo, Ming Lin, Michael Mader, Robert Hindes, Efsevia Albanis, William T Symonds, Michelle M Berrey, Andrew Muir, Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial, The Lancet Infectious Diseases, 2013, 13, 5, 401

    CrossRef

  68. 68
    Kris V Kowdley, Eric Lawitz, Israel Crespo, Tarek Hassanein, Mitchell N Davis, Michael DeMicco, David E Bernstein, Nezam Afdhal, John M Vierling, Stuart C Gordon, Jane K Anderson, Robert H Hyland, Hadas Dvory-Sobol, Di An, Robert G Hindes, Efsevia Albanis, William T Symonds, M Michelle Berrey, David R Nelson, Ira M Jacobson, Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, The Lancet, 2013,

    CrossRef

  69. 69
    Qianqian Zhu, Na Li, Qunying Han, Pingping Zhang, Cuiling Yang, Xiaoyan Zeng, Yanping Chen, Yi Lv, Xi Liu, Zhengwen Liu, Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis, Antiviral Research, 2013, 98, 3, 373

    CrossRef

  70. You have free access to this content70
    D. M. Hotho, J. de Bruijne, M. Spaan, M. A. Treitel, A. Boonstra, R. J. de Knegt, H. L. A. Janssen, H. W. Reesink, Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up, Journal of Viral Hepatitis, 2013, 20, 4
    Direct Link:
  71. 71
    L. H. Nguyen, M. H. Nguyen, Systematic review: Asian patients with chronic hepatitis C infection, Alimentary Pharmacology & Therapeutics, 2013, 37, 10
    Direct Link:
  72. 72
    A. Carlson, Z. Gregorich, R. Striker, Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity, Clinical Infectious Diseases, 2013, 56, 4, 552

    CrossRef

  73. 73
    Vincent Soriano, Pablo Labarga, Jose V. Fernández-Montero, Jose M. Benito, Eva Poveda, Norma Rallon, Clara Sánchez, Eugenia Vispo, Pablo Barreiro, The changing face of hepatitis C in the new era of direct-acting antivirals, Antiviral Research, 2013, 97, 1, 36

    CrossRef

  74. 74
    John W. Ward, The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States, Clinics in Liver Disease, 2013, 17, 1, 1

    CrossRef

  75. 75
    J. Kieran, S. Schmitz, A. O'Leary, C. Walsh, C. Bergin, S. Norris, M. Barry, The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1, Clinical Infectious Diseases, 2013, 56, 2, 228

    CrossRef

  76. 76
    David Padua, Sherona Bau, Sammy Saab, Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents, Current Hepatitis Reports, 2013, 12, 1, 13

    CrossRef

  77. 77
    Masaru Enomoto, Akihiro Tamori, Sawako Kobayashi, Shuji Iwai, Hiroyasu Morikawa, Norifumi Kawada, Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?, Journal of Gastroenterology, 2013, 48, 4, 555

    CrossRef

  78. 78
    Jean-Michel Pawlotsky, Treatment of Hepatitis C: How Will We Use Viral Kinetics, Response-Guided Therapy?, Current Gastroenterology Reports, 2013, 15, 2

    CrossRef

  79. 79
    M. F. Donato, A. J. Bastiampillai, M. Manini, S. Monico, Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients, Journal of Antimicrobial Chemotherapy, 2013, 68, 4, 974

    CrossRef

  80. 80
    A. Mangia, L. Mottola, V. Piazzolla, Update on the Treatment of Patients With Non-Genotype 1 Hepatitis C Virus Infection, Clinical Infectious Diseases, 2013, 56, 9, 1294

    CrossRef

  81. 81
    Dimitrios Vassilopoulos, Leonard H. Calabrese, Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV, Current Rheumatology Reports, 2013, 15, 4

    CrossRef

  82. 82
    Tomohiro Tanaka, Nazia Selzner, George Therapondos, Eberhard L. Renner, Leslie B. Lilly, Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients, Transplant International, 2013, 26, 1
    Direct Link:
  83. 83
    Tatsuo Kanda, Osamu Yokosuka, Masao Omata, Emerging Therapeutic Options for Hepatitis C, 2013,

    CrossRef

  84. 84
    Sriparna Ghosh, Keith J. Kaplan, Laura W. Schrum, Herbert L. Bonkovsky, 2013,

    CrossRef

  85. You have free access to this content85
    Doris B. Strader, Leonard B. Seeff, A brief history of the treatment of viral hepatitis C, Clinical Liver Disease, 2012, 1, 1
    Direct Link:
  86. 86
    Fabrizio Fabrizi, Giovanni Battista Fogazzi, Donata Cresseri, Patrizia Passerini, Paul Martin, Maria Francesca Donato, Maria Grazia Rumi, Piergiorgio Messa, Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis: Case Report and Review of the Literature, Kidney and Blood Pressure Research, 2012, 35, 6, 687

    CrossRef

  87. 87
    Andrew J. Muir, Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection, Infectious Disease Clinics of North America, 2012, 26, 4, 893

    CrossRef

  88. 88
    Pankaj Puri, Vivek A Saraswat, Back from the Future: Treating Hepatitis C Virus with Conventional Interferon, Journal of Clinical and Experimental Hepatology, 2012, 2, 1, 3

    CrossRef

  89. 89
    Christopher E. McGowan, Michael W. Fried, Barriers to hepatitis C treatment, Liver International, 2012, 32,
    Direct Link:
  90. 90
    Karly P. Garnock-Jones, Boceprevir, Drugs, 2012, 72, 18, 2431

    CrossRef

  91. 91
    Syed-Mohammed Jafri, Stuart C. Gordon, Care of the Cirrhotic Patient, Infectious Disease Clinics of North America, 2012, 26, 4, 979

    CrossRef

  92. 92
    Maribel Rodríguez-Torres, Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient, Expert Review of Anti-infective Therapy, 2012, 10, 10, 1117

    CrossRef

  93. 93
    Johannes Vermehren, Simone Susser, Annemarie Berger, Dany Perner, Kai-Henrik Peiffer, Regina Allwinn, Stefan Zeuzem, Christoph Sarrazin, Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection, Journal of Clinical Virology, 2012, 55, 1, 17

    CrossRef

  94. 94
    Kyung-Ah Kim, Comparison of Efficacy of Peginterferon and Ribavirin Combination Therapy for Chronic Hepatitis C among Korean, Caucasian and Other Asians, The Korean Journal of Gastroenterology, 2012, 60, 5, 273

    CrossRef

  95. 95
    Melissa R. Stein, Irene J. Soloway, Karen S. Jefferson, Robert J. Roose, Julia H. Arnsten, Alain H. Litwin, Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program, Journal of Substance Abuse Treatment, 2012, 43, 4, 424

    CrossRef

  96. 96
    P. O. Coffin, J. D. Scott, M. R. Golden, S. D. Sullivan, Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C, Clinical Infectious Diseases, 2012, 54, 9, 1259

    CrossRef

  97. 97
    Calogero Cammà, Salvatore Petta, Marco Enea, Raffaele Bruno, Fabrizio Bronte, Vincenza Capursi, Americo Cicchetti, Giorgio L. Colombo, Vito Di Marco, Antonio Gasbarrini, Antonio Craxì, Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C, Hepatology, 2012, 56, 3
    Direct Link:
  98. 98
    Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, Claudia Martorell, Greg T Everson, Harvey A Tatum, Christophe Hézode, Joseph K Lim, Jean-Pierre Bronowicki, Gary A Abrams, Norbert Bräu, David W Morris, Paul J Thuluvath, Robert W Reindollar, Philip D Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A Hughes, Steven Schnittman, Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial, The Lancet Infectious Diseases, 2012, 12, 9, 671

    CrossRef

  99. 99
    I. A. Rowe, D. D. Houlihan, D. J. Mutimer, Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit, Alimentary Pharmacology & Therapeutics, 2012, 36, 7
    Direct Link:
  100. 100
    Heidar Sharafi, Ali Pouryasin, Seyed Moayed Alavian, Bita Behnava, Maryam Keshvari, Leila Mehrnoush, Shima Salimi, Osveh Kheradvar, Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response, Hepatitis Monthly, 2012, 12, 3, 190

    CrossRef

  101. 101
    Eva Poveda, Vincent Soriano, Drug resistance testing in hepatitis C therapy, Future Virology, 2012, 7, 3, 309

    CrossRef

  102. 102
    E. William St.Clair, Editorial: Hepatitis C virus–related cryoglobulinemic vasculitis: Emerging trends in therapy, Arthritis & Rheumatism, 2012, 64, 3
    Direct Link:
  103. 103
    Michael E. Trigg, Emerging treatment advances in chronic hepatitis C, Community Oncology, 2012,

    CrossRef

  104. 104
    A. Andriulli, A. Iacobellis, M. R. Valvano, F. Spirito, A. Ippolito, F. Bossa, F. Terracciano, R. Fontana, G. Niro, Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin, Digestive Diseases and Sciences, 2012,

    CrossRef

  105. 105
    Alessio Aghemo, Sherrie Bhoori, Stella De nicola, Vincenzo Mazzaferro, Massimo Colombo, Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection, Hepatitis Monthly, 2012, 12, 6, 411

    CrossRef

  106. 106
    Charles L. McDowell, First Hand: The Surgeon and Hepatitis C, The Journal of Hand Surgery, 2012, 37, 8, 1693

    CrossRef

  107. 107
    Maribel Rodríguez-Torres, Focus on drug interactions, Current Opinion in Infectious Diseases, 2012, 1

    CrossRef

  108. 108
    C Torti, M Zazzi, L Abenavoli, F Trapasso, F Cesario, D Corigliano, L Cosco, C Costa, RL Curia, M De Rosa, G Foti, C Giraldi, R Leone, MC Liberto, D Lucchino, N Marascio, R Masciari, G Matera, V Pisani, N Serrao, L Surace, E Zicca, F Castelli, M Ciccozzi, M Puoti, A Focà, Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology), BMC Infectious Diseases, 2012, 12, Suppl 2, S9

    CrossRef

  109. 109
    Valérie Martel-Laferrière, Douglas T Dieterich, GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV, Future Virology, 2012, 7, 6, 537

    CrossRef

  110. 110
    C. Cooper, Hepatitis C Treatment Highlights From the 2011 American Association for the Study of Liver Disease Meeting, Clinical Infectious Diseases, 2012, 55, 3, 418

    CrossRef

  111. You have free access to this content111
    Andres F. Carrion, Paul Martin, Hepatitis C viral infection in patients with chronic kidney disease, Clinical Liver Disease, 2012, 1, 3
    Direct Link:
  112. You have free access to this content112
    Ranjeeta Bahirwani, K. Rajender Reddy, Hepatitis C viral infection in patients with cirrhosis, Clinical Liver Disease, 2012, 1, 3
    Direct Link:
  113. 113
    J. W. Ward, R. O. Valdiserri, H. K. Koh, Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice, Clinical Infectious Diseases, 2012, 55, suppl 1, S58

    CrossRef

  114. 114
    Varun Saxena, Norah Terrault, Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies, Current Opinion in Organ Transplantation, 2012, 17, 3, 216

    CrossRef

  115. 115
    Fabrizio Fabrizi, Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence, Scientifica, 2012, 2012, 1

    CrossRef

  116. 116
    David R. Nelson, Donald M. Jensen, Mark S. Sulkowski, Greg Everson, Michael W. Fried, Stuart C. Gordon, Ira Jacobson, Nancy S. Reau, Kenneth Sherman, Nora Terrault, David Thomas, Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy, Hepatitis Research and Treatment, 2012, 2012, 1

    CrossRef

  117. 117
    Seyed Moayed Alavian, Hossain Jabbari, Nasser Ebrahimi Daryani, Mohammad Torabi nami, Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran, Hepatitis Monthly, 2012, 12, 7, 423

    CrossRef

  118. 118
    J. de la Revilla Negro, J.L. Martínez Porras, K. Torres Cruz, J.L. Calleja Panero, Hepatitis crónica por virus de la hepatitis C. Historia natural y tratamiento, Medicine - Programa de Formación Médica Continuada Acreditado, 2012, 11, 9, 529

    CrossRef

  119. 119
    Patrick Marcellin, Hugo Cheinquer, Manuela Curescu, Geoffrey M. Dusheiko, Peter Ferenci, Andrzej Horban, Donald Jensen, Gabriella Lengyel, Alessandra Mangia, Denis Ouzan, Massimo Puoti, Maribel Rodriguez-Torres, Mitchell L. Shiffman, Manuela Schmitz, Fernando Tatsch, Mario Rizzetto, High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 2012, 56, 6
    Direct Link:
  120. 120
    Nick Walsh, Lisa Maher, HIV and viral hepatitis C coinfection in people who inject drugs, Current Opinion in HIV and AIDS, 2012, 7, 4, 339

    CrossRef

  121. 121
    Christoph T. Berger, Arthur Y. Kim, IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment, Infectious Disease Clinics of North America, 2012, 26, 4, 863

    CrossRef

  122. 122
    Esther Molina Pérez, Javier Fernández Castroagudín, Enrique Domínguez Muñoz, Indicaciones actuales de tratamiento triple para la hepatitis C, Gastroenterología y Hepatología, 2012, 35, 4, 266

    CrossRef

  123. 123
    L. Fathauer, J. Meek, Initial implementation and evaluation of a Hepatitis C treatment clinical decision support system (CDSS), Applied Clinical Informatics, 2012, 3, 3, 337

    CrossRef

  124. 124
    J. Liu, J. Florian, D. Birnkrant, J. Murray, P. R. Jadhav, Interferon Responsiveness Does Not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions, Clinical Infectious Diseases, 2012, 55, 5, 639

    CrossRef

  125. 125
    Alexander Monto, James Ryan, Is IL28B genotype associated with more than one aspect of viral clearance?, Hepatology, 2012, 56, 6
    Direct Link:
  126. You have free access to this content126
    Syed-Mohammed R. Jafri, Stuart C. Gordon, Is there still a role for liver biopsy in managing hepatitis C virus infections?, Clinical Liver Disease, 2012, 1, 2
    Direct Link:
  127. 127
    Anca Trifan, Carol Stanciu, Liver Biopsy Has a Low Diagnostic Performance for Intermediate Stages of Fibrosis, Clinical Gastroenterology and Hepatology, 2012, 10, 12, 1420

    CrossRef

  128. 128
    José Vicente Fernández-Montero, Vicente Soriano, Management of hepatitis C in HIV and/or HBV co-infected patients, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 517

    CrossRef

  129. 129
    A. Sidney Barritt, Michael W. Fried, Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus, Gastroenterology, 2012, 142, 6, 1314

    CrossRef

  130. 130
    Jian Chen, Jian Shi, Wei-Fen Xie, Xin Zeng, Yong Lin, Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients, International Journal of Infectious Diseases, 2012, 16, 10, e748

    CrossRef

  131. 131
    Cara L. Mack, Regino P. Gonzalez-Peralta, Nitika Gupta, Daniel Leung, Michael R. Narkewicz, Eve A. Roberts, Philip Rosenthal, Kathleen B. Schwarz, NASPGHAN Practice Guidelines, Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 6, 838

    CrossRef

  132. 132
    Benjamin Maasoumy, Heiner Wedemeyer, Natural history of acute and chronic hepatitis C, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 401

    CrossRef

  133. 133
    Snawar Hussain, Naina Barretto, Susan L Uprichard, New hepatitis C virus drug discovery strategies and model systems, Expert Opinion on Drug Discovery, 2012, 7, 9, 849

    CrossRef

  134. 134
    D N Assis, J K Lim, New Pharmacotherapy for Hepatitis C, Clinical Pharmacology & Therapeutics, 2012, 92, 3, 294

    CrossRef

  135. 135
    Stéphane Chevaliez, Christophe Rodriguez, Jean–Michel Pawlotsky, New Virologic Tools for Management of Chronic Hepatitis B and C, Gastroenterology, 2012, 142, 6, 1303

    CrossRef

  136. 136
    Laurent Castera, Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C, Gastroenterology, 2012, 142, 6, 1293

    CrossRef

  137. 137
    Michael O. Clarke, Daniel Byun, Xiaowu Chen, Edward Doerffler, Stephanie A. Leavitt, X. Christopher Sheng, Cheng Y. Yang, Choung U. Kim, Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 2, 1095

    CrossRef

  138. 138
    José-Luis Calleja, Javier García-Samaniego, Belén Ruiz-Antorán, María Trapero, Rosa Morillas, Juan Revilla, José Carlos Erdozaín, María-Dolores Espinosa, Dolores Suárez, Ricard Solá, Manuel Romero-Gómez, Fernando Baños, Marco-Antonio Álvarez, Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels, Journal of Gastroenterology and Hepatology, 2012, 27, 11
    Direct Link:
  139. 139
    Stela Vujosevic, Diego Tempesta, Franco Noventa, Edoardo Midena, Giada Sebastiani, Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening, Hepatology, 2012, 56, 2
    Direct Link:
  140. 140
    Edoardo G. Giannini, Simona Marenco, Valentina Fazio, Giulia Pieri, Vincenzo Savarino, Antonino Picciotto, Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy, Liver International, 2012, 32, 7
    Direct Link:
  141. 141
    David R Booth, Golo Ahlenstiel, Jacob George, Pharmacogenomics of hepatitis C infections: personalizing therapy, Genome Medicine, 2012, 4, 12, 99

    CrossRef

  142. 142
    Ezequiel Ridruejo, Predictors of response to chronic hepatitis C treatment, Future Virology, 2012, 7, 11, 1089

    CrossRef

  143. 143
    Anna S. Lok, David F. Gardiner, Eric Lawitz, Claudia Martorell, Gregory T. Everson, Reem Ghalib, Robert Reindollar, Vinod Rustgi, Fiona McPhee, Megan Wind-Rotolo, Anna Persson, Kurt Zhu, Dessislava I. Dimitrova, Timothy Eley, Tong Guo, Dennis M. Grasela, Claudio Pasquinelli, Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1, New England Journal of Medicine, 2012, 366, 3, 216

    CrossRef

  144. 144
    J. Hugueny, P. Fagnoni, M.-H. Guignard, Prise en charge de l’hépatite C chronique : les dernières avancées thérapeutiques, Le Pharmacien Hospitalier et Clinicien, 2012,

    CrossRef

  145. 145
    Brian L Pearlman, Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care, The Lancet Infectious Diseases, 2012, 12, 9, 717

    CrossRef

  146. 146
    M. Palmer, R. Rubin, V. Rustgi, Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1, Alimentary Pharmacology & Therapeutics, 2012, 36, 4
    Direct Link:
  147. 147
    Harrys A. Torres, Marta Davila, Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer, Nature Reviews Clinical Oncology, 2012, 9, 3, 156

    CrossRef

  148. 148
    Dae Won Jun, Won Young Tak, Si Hyun Bae, Youn Jae Lee, Recent trends in the treatment of chronic hepatitis C, The Korean Journal of Hepatology, 2012, 18, 1, 22

    CrossRef

  149. 149
    José Velosa, Luís Caldeira, Ana I. Lopes, Luís Guerreiro, Rui Marinho, Recomendações para a terapêutica da hepatite C, GE Jornal Português de Gastrenterologia, 2012, 19, 3, 133

    CrossRef

  150. 150
    Heiner Wedemeyer, Donald M. Jensen, Eliot Godofsky, Nina Mani, Jean-Michel Pawlotsky, Veronica Miller, Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents, Hepatology, 2012, 56, 6
    Direct Link:
  151. 151
    Ira M. Jacobson, Patrick Marcellin, Stefan Zeuzem, Mark S. Sulkowski, Rafael Esteban, Fred Poordad, Savino Bruno, Margaret H. Burroughs, Lisa D. Pedicone, Navdeep Boparai, Weiping Deng, Mark J. DiNubile, Keith M. Gottesdiener, Clifford A. Brass, Janice K. Albrecht, Jean-Pierre Bronowicki, Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin, Hepatology, 2012, 56, 2
    Direct Link:
  152. 152
    Patrick Marcellin, Stuart K Roberts, K Rajender Reddy, Stephen A Harrison, Donald M Jensen, Stephanos Hadziyannis, Moises Diago, Martin Weltman, Diethelm Messinger, Fernando Tatsch, Mario Rizzetto, Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies, Expert Opinion on Drug Safety, 2012, 11, 6, 901

    CrossRef

  153. 153
    Oscar Belda, Paul Targett-Adams, Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein, Virus Research, 2012, 170, 1-2, 1

    CrossRef

  154. 154
    Harjit Bhogal, Richard K. Sterling, Staging of Liver Disease, Infectious Disease Clinics of North America, 2012, 26, 4, 849

    CrossRef

  155. 155
    Andrew J. Muir, Surgical Clearance for the Patient with Chronic Liver Disease, Clinics in Liver Disease, 2012, 16, 2, 421

    CrossRef

  156. 156
    J. Berenguer, E. Rodriguez, P. Miralles, M. A. Von Wichmann, J. Lopez-Aldeguer, J. Mallolas, M. J. Galindo, E. Van Den Eynde, M. J. Tellez, C. Quereda, A. Jou, J. Sanz, C. Barros, I. Santos, F. Pulido, J. M. Guardiola, E. Ortega, R. Rubio, J. J. Jusdado, M. L. Montes, G. Gaspar, H. Esteban, J. M. Bellon, J. Gonzalez-Garcia, Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus, Clinical Infectious Diseases, 2012, 55, 5, 728

    CrossRef

  157. 157
    Min Ding, Feng He, Thomas W. Hudyma, Xiaofan Zheng, Michael A. Poss, John F. Kadow, Brett R. Beno, Karen L. Rigat, Ying-Kai Wang, Robert A. Fridell, Julie A. Lemm, Dike Qiu, Mengping Liu, Stacey Voss, Lenore A. Pelosi, Susan B. Roberts, Min Gao, Jay Knipe, Robert G. Gentles, Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: Potent allosteric inhibitors of the hepatitis C virus NS5B polymerase, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 8, 2866

    CrossRef

  158. 158
    Caroline M. Perry, Telaprevir, Drugs, 2012, 72, 5, 619

    CrossRef

  159. 159
    Edward Kim, Yuan Yuan Chen, Eric M Yoshida, Telaprevir for retreatment of HCV infection: review of the REALIZE trial, Future Virology, 2012, 7, 5, 435

    CrossRef

  160. 160
    Christoph R. Werner, Daniel P. Egetemeyr, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Nisar P. Malek, Christoph P. Berg, Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data, Liver Transplantation, 2012, 18, 12
    Direct Link:
  161. 161
    Samuel James Matthews, Jason W. Lancaster, Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor, Clinical Therapeutics, 2012, 34, 9, 1857

    CrossRef

  162. 162
    Karly S Louie, Samantha St Laurent, Ulla M Forssen, Linda M Mundy, Jeanne M Pimenta, The high comorbidity burden of the hepatitis C virus infected population in the United States, BMC Infectious Diseases, 2012, 12, 1, 86

    CrossRef

  163. 163
    Erin T. Jenkins, Donald M. Jensen, The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus, Infectious Disease Clinics of North America, 2012, 26, 4, 879

    CrossRef

  164. You have free access to this content164
    Naveen Gara, Marc G. Ghany, The new standard of HCV therapy: Retreatment in experienced patients, Clinical Liver Disease, 2012, 1, 1
    Direct Link:
  165. You have free access to this content165
    Saurabh Agrawal, Paul Y. Kwo, The new standard of HCV therapy: Treatment in therapy-naive patients , Clinical Liver Disease, 2012, 1, 1
    Direct Link:
  166. 166
    Laurent Chiche, Stanislas Bataille, Gilles Kaplanski, Noemie Jourde, The Place of Immunotherapy in the Management of HCV-Induced Vasculitis: An Update, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  167. 167
    Michael P. Collins, The vasculitic neuropathies, Current Opinion in Neurology, 2012, 25, 5, 573

    CrossRef

  168. 168
    Takeshi Nishimura, Kanji Yamaguchi, Hiroaki Hashimoto, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Masafumi Sakamoto, Naoki Ohnish, Yasuyuki Nagao, Mika Okita, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh, Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy, Hepatology Research, 2012, 42, 10
    Direct Link:
  169. 169
    Giuseppe Indolfi, Alessandro Nesi, Massimo Resti, Treatment of chronic hepatitis B and C in children, Future Virology, 2012, 7, 10, 955

    CrossRef

  170. 170
    Shiv K. Sarin, Chandan K. N. Kumar, Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies, Liver International, 2012, 32,
    Direct Link:
  171. 171
    Roberta D’Ambrosio, Alessio Aghemo, Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks, Hepatitis Monthly, 2012, 12, 6, 361

    CrossRef

  172. 172
    Rafael Esteban, Maria Buti, Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 445

    CrossRef

  173. 173
    Alessio Aghemo, Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection, Digestive Diseases and Sciences, 2012, 57, 8, 1977

    CrossRef

  174. 174
    Helen S Yee, Michael F Chang, Christine Pocha, Joseph Lim, David Ross, Timothy R Morgan, Alexander Monto, Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office, The American Journal of Gastroenterology, 2012, 107, 5, 669

    CrossRef

  175. 175
    Muhamad Aly Rifai, Mouhamed Amr Sabouni, Utilizing genomic polymorphisms to personalize hepatitis C therapies, Current Opinion in Organ Transplantation, 2012, 17, 2, 198

    CrossRef

  176. 176
    Stéphane Chevaliez, Jean-Michel Pawlotsky, Virology of hepatitis C virus infection, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 381

    CrossRef

  177. 177
    Ann D Kwong, Robert S Kauffman, Patricia Hurter, Peter Mueller, Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus, Nature Biotechnology, 2011, 29, 11, 993

    CrossRef

  178. 178
    Evaldo Stanislau Affonso de Araújo, Hepatitis C therapy in 2011: is less more, is more less?, The Brazilian Journal of Infectious Diseases, 2011, 15, 6, 508

    CrossRef

  179. 179
    Heidar Sharafi, Seyed Moayed Alavian, IL28B polymorphism,Explanation for Different Responses to Therapy in Hepatitis C Patients, Hepatitis Monthly, 2011, 11, 12, 958

    CrossRef

View Full Article (HTML) Get PDF (270K)